687 related articles for article (PubMed ID: 9154331)
1. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
2. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function.
Gantner F; Schudt C; Wendel A; Hatzelmann A
Pulm Pharmacol Ther; 1999; 12(6):377-86. PubMed ID: 10587479
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
8. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
9. Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle.
Challiss RA; Adams D; Mistry R; Nicholson CD
Br J Pharmacol; 1998 May; 124(1):47-54. PubMed ID: 9630342
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Milara J; Navarro A; Almudéver P; Lluch J; Morcillo EJ; Cortijo J
Clin Exp Allergy; 2011 Apr; 41(4):535-46. PubMed ID: 21395877
[TBL] [Abstract][Full Text] [Related]
11. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
12. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
13. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
15. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.
Smith SJ; Cieslinski LB; Newton R; Donnelly LE; Fenwick PS; Nicholson AG; Barnes PJ; Barnette MS; Giembycz MA
Mol Pharmacol; 2004 Dec; 66(6):1679-89. PubMed ID: 15371556
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
Kumari M; Cover PO; Poyser RH; Buckingham JC
Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
[TBL] [Abstract][Full Text] [Related]
17. Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.
Seldon PM; Giembycz MA
Br J Pharmacol; 2001 Sep; 134(1):58-67. PubMed ID: 11522597
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
[TBL] [Abstract][Full Text] [Related]
20. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]